http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2318502-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2006-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2318502-C2 |
| titleOfInvention | Method for treating uterine choriocarcinoma cases |
| abstract | FIELD: medicine. n SUBSTANCE: method involves applying endolymphatic- and autohemochemotherapy. Stage I of choriocarcinoma involves administering Methotrexate 20 mg/m 2 as endolymphatic therapy at 1, 4, 8, 11, 15 and 18-th day; Rubomycin 30 mg/m 2 at 1, 4, 8, 11, 15 and 18-th day Vinblastin - 15 mg/m 2 at 1, 8 and 16-th day as autohemochemotherapy. Stage II of the disease involves administering Methotrexate 200 mg/m 2 at the first day as endolymphatic therapy; Vincristin - 1.5 mg/m 2 at 5,11, and 17-th day, Rubomycin 30 mg/m 2 at 5, 8, 11, 14, 17 and 20-th day in a 21 days long course with 3 weeks long pause as autohemochemotherapy. The number of courses is 1-3. Stage III of the disease involves administering Methotrexate 200 mg/m 2 as endolymphatic therapy, Etoposide -100 mg/m 2 , Kosmogen - 0.5 mg as autohemochemotherapy at the first day; Kosmogen - 0.5 mg as autohemochemotherapy at the second day; Vincristin - 1.0 mg/m 2 Cyclophosphane 600 mg/m 2 , in 8 days long courses with 3-4 weeks interval and the number of courses is equal to 2-3. n EFFECT: eliminated metastases in the region of sexual organs and lungs; repaired menstrual cycle. |
| priorityDate | 2006-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.